Anna Protopapas, a director at Mersana Therapeutics Inc . (NASDAQ:MRSN), recently reported a sale of company stock, according to a filing with the Securities and Exchange Commission. On January 15, ...
26mon MSN
Infosys raised its revenue forecast for the fourth straight quarter, projecting 4.5-5% growth for the 2024-25 fiscal year.
48m
Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback